

Special Bulletin

For professional and facility providers in NY

December 10, 2024

Medical Policy L-124 Somatic Biomarker Testing – On Hold Until Further Notice

Medical Policy L-124 Somatic Biomarker Testing for Solid Tumors, originally scheduled to be published on Dec. 2, 2024, is on hold until further notice.

The following entities, which serve the noted regions, are independent licensees of the Blue Cross Blue Shield Association: Western NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Cross Blue Shield. Northeastern NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Shield.

All references to "Highmark" in this document are references to the Highmark company that is providing the member's health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.

